erythromycin has been researched along with pc190723 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bi, F; Liu, X; Ma, S; Qin, Y; Song, D; Teng, Y; Zhang, N; Zhang, P | 1 |
| Bi, F; Liu, X; Ma, S; Qin, Y; Song, D; Teng, Y; Zhang, N | 1 |
2 other study(ies) available for erythromycin and pc190723
| Article | Year |
|---|---|
Discovery of 1,3,4-oxadiazol-2-one-containing benzamide derivatives targeting FtsZ as highly potent agents of killing a variety of MDR bacteria strains.
Topics: Bacterial Proteins; Benzamides; Cytoskeletal Proteins; Methicillin-Resistant Staphylococcus aureus | 2019 |
Design, synthesis of novel 4,5-dihydroisoxazole-containing benzamide derivatives as highly potent FtsZ inhibitors capable of killing a variety of MDR Staphylococcus aureus.
Topics: Animals; Anti-Bacterial Agents; Bacterial Proteins; Benzamides; Binding Sites; Cell Survival; Cytoskeletal Proteins; Drug Design; Drug Resistance, Bacterial; Drug Stability; Gram-Negative Bacteria; Gram-Positive Bacteria; HeLa Cells; Humans; Isoxazoles; Methicillin-Resistant Staphylococcus aureus; Mice; Microbial Sensitivity Tests; Molecular Docking Simulation; Structure-Activity Relationship | 2020 |